Navigation Links
Seaside publishes research supporting disease-modifying potential of STX209 for fragile X syndrome

CAMBRIDGE, Mass., (Embargoed until September 19, 2012, 2:00 PM US Eastern Time) Seaside Therapeutics today announced the publication of two papers in Science Translational Medicine, supporting its lead candidate, STX209 (arbaclofen), for the treatment of fragile X syndrome (FXS). The works presented highlight STX209 as a potential disease-modifying drug in preclinical studies, with improvement in social function in a clinical trial of patients with FXS.

"In preclinical results, we demonstrate that STX209 treatment corrects core aspects of FXS pathophysiology in the fragile X mouse model, leading us to conclude that STX209 is a disease-modifying drug with the potential to significantly improve the lives of patients with fragile X," said Randall Carpenter, MD, President and Chief Executive Officer of Seaside Therapeutics. "In fact, in our Phase 2 clinical trial, we observed statistically significant improvements in social avoidance, a core symptom of fragile X syndrome that is characterized by behaviors such as preference to be alone and being withdrawn or isolated. Social avoidance is also a core symptom of autism spectrum disorders, suggesting STX209 could have a positive effect in this larger patient population. Together, these results support our continued development of STX209, which is currently enrolling patients in a Phase 3 study in fragile X syndrome and recently completed enrollment in a Phase 2b study in autism spectrum disorders."

"There are currently no FDA approved therapeutics that address the core symptoms of fragile X syndrome, leaving patients and their caregivers with limited treatment options," said Elizabeth Berry-Kravis, MD, PhD, Professor of Pediatrics, Neurology, and Biochemistry at Rush University Medical Center in Chicago, and the lead author of the paper on the Phase 2 study results. "We are very excited about the clinically meaningful improvements in social impairment observed to date in patients receiving STX209 marking the first time a drug candidate has positively impacted a specific core symptom of fragile X. With continued success in ongoing clinical trials, I am hopeful that STX209 may be able to transform the treatment paradigm for fragile X syndrome which would confirm what I have believed all along that intellectual disability is not, as previously understood, an immutable condition."

FXS is the most common inherited cause of intellectual disability (mental retardation) and the most prevalent known cause of autism. FXS is caused by the mutation of a single gene known as FMR1. FMR1 codes for a protein called fragile X mental retardation protein (FMRP) that is necessary for normal brain development. Without FMRP, patients exhibit several changes in their brains that underlie the cognitive and behavioral deficits associated with FXS. These changes include: alterations of neuronal morphology and an imbalance between excitatory and inhibitory neurotransmission in the brain. In addition, changes in localized protein synthesis have been observed in mouse models of FXS.

In the paper entitled "Postnatal pharmacological activation of the GABA-B receptor has potential to be disease-modifying in fragile X syndrome," the researchers tested whether STX209 was effective in reversing the hallmark changes in the brains of mice lacking the Fmr1 gene. In vitro application of STX209 to the hippocampus of mice lacking Fmr1 reduced levels of localized protein synthesis to that of normal mice. Additionally, this treatment reduced a known functional consequence of increased protein synthesis, AMPA receptor internalization, to levels found in normal mice. Furthermore, in vivo administration of STX209 corrected alterations in neuronal morphology specific to Fmr1-deficient mice and FXS patients, but STX209 did not alter neuronal morphology in normal mice and STX209 also reduced protein translation in mice lacking Fmr1, but not in normal mice. Of note, the magnitude of effect observed with STX209 is comparable to that reported for selective mGluR5 antagonists. These results demonstrate that STX209 has the potential to modify the underlying disease of patients with FXS and support the development of STX209 in the clinic.

Study authors included Christina Henderson, Aileen M. Healy, Matthew Shumway, Rebecca S. Hammond, Friso R. Postima, Christopher Brynczka, Roger Rush and Randall L. Carpenter of Seaside Therapeutics; Lasani Wijetunge and Peter C. Kind of the University of Edinburgh; Mika Nakamoto Kinoshita and Stephen T. Warren of Emory University; Alicia Thomas and Richard Paylor of Baylor College of Medicine; Peter W. Vanderklish of The Scripps Research Institute; and Mark F. Bear of the Massachusetts Institute of Technology.

The accompanying paper, "Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, Phase 2 trial," detailed the results previously announced from the Company's Phase 2 trial. The randomized, double-blind, placebo-controlled Phase 2 study was designed to evaluate the clinical effects of STX209 in 63 subjects, age 6-40 years, with a full mutation of the FMR1 gene. As previously reported, STX209 was well-tolerated and no metabolic side effects were observed. The most common adverse events in subjects receiving STX209 were upper respiratory infections (13%), sedation (8%) and headache (8%), compared to 10%, 2% and 2%, respectively, while receiving placebo. In per-protocol analyses, improvement was seen on the visual analog scale (VAS) ratings of parent-nominated problem behaviors and positive trends were observed on multiple global measures. While improvement was noted on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), the study's primary endpoint, the magnitude was comparable to that observed on placebo and did not achieve statistical significance.

Social avoidance is a core symptom of FXS. Post-hoc analysis of ABC-Social Avoidance scale, a newly validated scale for the assessment of FXS, revealed a significant beneficial treatment effect in the full study population (p<0.01). A post-hoc subgroup of 27 subjects with more severe social impairment showed improvements on the Vineland II-Socialization raw score (p=0.03), the ABC-Social Avoidance scale (p=0.04) and on all global measures. The results suggest that STX209 has the potential to improve social function and behavior in patients with FXS.

Study authors included Elizabeth M. Berry-Kravis of Rush University Medical Center, Randi J. Hagerman, David R. Hessl, Yi Mu and Danh V. Nguyen of the University of California Davis; Barbara Rathmell, Peter Zarevics, Maryann Cherubini, Karen Walton-Bowen, Paul P. Wang and Randall L. Carpenter of Seaside Therapeutics; Joseph Gonzalez-Heydrich of Children's Hospital Boston; and Mark F. Bear of the Massachusetts Institute of Technology.


Contact: Kari Watson
MacDougall Biomedical Communications, Inc.

Related biology technology :

1. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
2. Nonprofit Consortium Publishes Review of Skullcap Adulteration
3. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
4. American Botanical Council Publishes a History of Adulteration
5. Stanford faculty awarded $2.2 million for innovative energy research
6. Electronics without current: Finnish team to research the future of nanoelectronics
7. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
8. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
9. Penn researchers make first all-optical nanowire switch
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing partnership between ... (OPBAP) has been formalized with the signing of a Memorandum of Understanding. , ... leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at ...
Breaking Biology Technology:
(Date:11/4/2015)... --> --> ... Transparency Market Research "Home Security Solutions Market - Global Industry ... 2022", the global home security solutions market is expected to reach ... market is estimated to expand at a CAGR of ... Rising security needs among customers at homes, the emergence ...
(Date:10/29/2015)...  The J. Craig Venter Institute (JCVI) policy group ... Biosecurity: Lessons Learned and Options for the Future," which ... Services guidance for synthetic biology providers has worked since ... --> --> Synthetic biology promises great ... pose unique biosecurity threats. It now is easier than ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):